Form 13-F position report

INDAPTUS THERAPEUTICS INC (DE)

Reported by MORGAN STANLEY

INDP CUSIP 45339J105 Manager CIK 0000895421

Reported 829 shares, unchanged from the prior quarter.

Reported value 3.3%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 829 Quarter-end amount reported
Reported value $1,583 Fair value at quarter end
Consecutive quarters held 8 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 2000
2022-03-31 0
2022-06-30 0
2022-09-30 0
2022-12-31 767
2023-03-31 1533
2023-06-30 1583
2023-09-30 2835
2023-12-31 1555
2024-03-31 1981
2024-06-30 1874
2024-09-30 1097
2024-12-31 744
2025-03-31 486
2025-06-30 0
2026-03-31 4909
2026-06-30 26808
2026-09-30 2905

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for INDAPTUS THERAPEUTICS INC (DE) held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 1,263 -7,673 (-85.9%) < 0.01% $2,905 2026-11-13
Q2 2026 Added 8,936 +6,239 (231.3%) < 0.01% $26,808 2026-08-13
Q1 2026 New 2,697 +2,697 (0.0%) < 0.01% $4,909 2026-05-15
Q2 2025 Reduced 0 -884 (-100.0%) 0 $0 2025-08-15
Q1 2025 Unchanged 884 0 (0.0%) < 0.01% $486 2025-05-15
Q4 2024 Unchanged 884 0 (0.0%) < 0.01% $744 2025-02-14
Q3 2024 Unchanged 884 0 (0.0%) < 0.01% $1,097 2024-11-14
Q2 2024 Unchanged 884 0 (0.0%) < 0.01% $1,874 2024-08-14
Q1 2024 Unchanged 884 0 (0.0%) < 0.01% $1,981 2024-05-15
Q4 2023 Reduced 884 -145 (-14.1%) < 0.01% $1,555 2024-02-13
Q3 2023 Added 1,029 +200 (24.1%) < 0.01% $2,835 2023-11-15
Q2 2023 Unchanged 829 0 (0.0%) < 0.01% $1,583 2023-08-14
Q1 2023 Added 829 +300 (56.7%) < 0.01% $1,533 2023-05-15
Q4 2022 Added 529 +352 (198.9%) < 0.01% $767 2023-02-14
Q3 2022 Unchanged 177 0 (0.0%) 0 $0 2022-11-14
Q2 2022 Added 177 +172 (3440.0%) 0 $0 2022-08-15
Q1 2022 Reduced 5 -360 (-98.6%) 0 $0 2022-05-13
Q4 2021 Unchanged 365 0 (0.0%) < 0.01% $2,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

17 managers reported INDAPTUS THERAPEUTICS INC (DE) for Q2 2023.

Managers reporting INDAPTUS THERAPEUTICS INC (DE) in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Unchanged 250,348 0 < 0.01% $478,165 8 qtrs
INVESTMENT HOUSE LLC Added 108,282 +12,653 0.02% $206,819 8 qtrs
GEODE CAPITAL MANAGEMENT LLC Unchanged 50,521 0 < 0.01% $92,453 8 qtrs
STRATEGY ASSET MANAGERS LLC Reduced 45,336 -10,000 0.02% $86,592 4 qtrs
Pine Valley Investments Ltd Liability Co Unchanged 44,420 0 < 0.01% $84,843 2 qtrs
Vivaldi Capital Management LP Unchanged 24,000 0 0.01% $45,840 6 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 20,800 +1,600 < 0.01% $40,000 5 qtrs
STATE STREET CORPORATION Unchanged 19,473 0 < 0.01% $35,636 6 qtrs
NORTHERN TRUST CORPORATION Unchanged 12,918 0 < 0.01% $24,673 6 qtrs
Tower Research Capital LLC TRC Reduced 5,665 -475 < 0.01% $10,820 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
665
Shared
0
None
164

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.